The therapeutic potential of ximelagatran to become the anticoagulant of choice in medicine: a review of recently completed clinical trials

Author： Salam Amar M   Al-Mousa Eyas N  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.6, 2004-06, pp. : 1423-1430

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Planned, ongoing and recently completed clinical trials for atherosclerosis prevention and regression: an update

By Mellies M.   McGovern M.  

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 1, 1997-01 ,pp. : 31-50

Informa Healthcare

Access to resources Recommend Favorite

&bgr;-blockers in heart failure: recently completed and ongoing clinical trials

By McAreavey D.   Exner D.V.   Curtin E.L.   Domanski M.J.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 2, 2000-02 ,pp. : 415-428

Informa Healthcare

Access to resources Recommend Favorite

Fibrinolytic and antithrombotic regimens in recently completed, ongoing and planned clinical trials in myocardial infarction

By Jong P.   Langer A.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 9, 1999-09 ,pp. : 1453-1465

Informa Healthcare

Access to resources Recommend Favorite

Hepatic Findings in Long-Term Clinical Trials of Ximelagatran

By Lee William M.  

Drug Safety, Vol. 28, Iss. 4, 2005-01 ,pp. : 351-370

Adis International

Access to resources Recommend Favorite

Clinical Trials and Evidence-Based Medicine

By  

Heart Drug, Vol. 2, Iss. 6, 2003-04 ,pp. : 269-272

Karger

Access to resources Recommend Favorite